IBSEN MEDICAL CONSULT ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.2% 10.8% 23.1% 23.0% 16.9%  
Credit score (0-100)  19 21 3 3 10  
Credit rating  BB BB B B BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  4.4 16.6 -9.6 -4.7 0.9  
EBITDA  4.4 16.6 -9.6 -4.7 0.9  
EBIT  1.6 5.2 -9.6 -4.7 0.9  
Pre-tax profit (PTP)  -1.5 1.0 -14.2 -7.0 -1.4  
Net earnings  -1.5 1.0 -14.2 -7.0 -1.4  
Pre-tax profit without non-rec. items  -1.5 1.0 -14.2 -7.0 -1.4  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  11.4 0.0 0.0 0.0 0.0  
Shareholders equity total  175 176 162 154 153  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  255 263 248 244 238  

Net Debt  -240 -263 -248 -244 -238  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  4.4 16.6 -9.6 -4.7 0.9  
Gross profit growth  -66.5% 276.5% 0.0% 50.5% 0.0%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  255 263 248 244 238  
Balance sheet change%  -0.4% 3.1% -5.8% -1.6% -2.2%  
Added value  4.4 16.6 -9.6 -4.7 0.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  9 -23 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 -1.0 -2.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  35.1% 31.1% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.6% 2.0% -3.7% -1.6% 0.8%  
ROI %  0.9% 2.9% -5.7% -2.4% 1.2%  
ROE %  -0.8% 0.6% -8.4% -4.4% -0.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  68.6% 66.9% 65.3% 63.3% 64.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -5,433.1% -1,581.3% 2,587.7% 5,147.4% -25,552.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  3.0 3.0 2.9 2.7 2.8  
Current Ratio  3.0 3.0 2.9 2.7 2.8  
Cash and cash equivalent  239.7 262.6 247.7 243.7 238.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  163.6 176.1 161.9 154.5 153.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -5 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -5 1  
EBIT / employee  0 0 0 -5 1  
Net earnings / employee  0 0 0 -7 -1